MKMinyeong Kim

Minyeong Kim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Minyeong Kim has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Structure and antiviral activity of a pectic polysaccharide from the root of Sanguisorba officinalis against enterovirus 71 in vitro/vivo

    by Minyeong Kim, Seong-Ryeol Kim, Jiye Park, Seo-Hyeon Mun, Myounghai Kwak, Hyun-Jeong Ko, Seung-Hoon Baek


  • Open Access

    Characterization of an Immune-Enhancing Polysaccharide Fraction Isolated from Heat-Processed Ginseng Derived from Panax ginseng C.A. Meyer

    by Sung Jin Kim, Myoung-Sook Shin, Minyeong Kim, Seung-Hoon Baek, Ki Sung Kang

    Panax ginseng C.A. Meyer (ginseng) has shown immune-enhancing activity in many studies. The purpose of the present study was to analyze the chemical properties of a polysaccharide fraction (SGP) purified from heat- processed ginseng and to evaluate its immune-enhancing activity using RAW264.7 macrophages. The results showed that SGP increased inducible nitric oxide synthase expression and nitric oxide production in RAW264.7 macrophages. In addition, SGP increased mRNA expression and secretion of interleukin 6 and tumor necrosis factor alpha. Immunoblotting results showed that SGP increased the phosphorylation of mitogen-activated protein kinases (MAPKs) and NF-κB subunit p65 at 500 μg/mL and 1000 μg/mL. Taken together, SGP can activate macrophages through the MAPK and NF-κB signaling pathways, and it may help maintain homeostasis during viral and bacterial infections.


  • Open Access

    Comparative Cerebroprotective Potential of d- and l-Carnosine Following Ischemic Stroke in Mice

    by Saurabh Jain, Eun-Sun Kim, Donghyun Kim, David Burrows, Milena De Felice, Minyeong Kim, Seung-Hoon Baek, Ali Ali, Jessica Redgrave, Thorsten R. Doeppner, et al.

    L-carnosine is an attractive therapeutic agent for acute ischemic stroke based on its robust preclinical cerebroprotective properties and wide therapeutic time window. However, large doses are needed for efficacy because carnosine is rapidly degraded in serum by carnosinases. The need for large doses could be particularly problematic when translating to human studies, as humans have much higher levels of serum carnosinases. We hypothesized that d-carnosine, which is not a substrate for carnosinases, may have a better pharmacological profile and may be more efficacious at lower doses than l-carnosine. To test our hypothesis, we explored the comparative pharmacokinetics and neuroprotective properties of d- and L-carnosine in acute ischaemic stroke in mice. We initially investigated the pharmacokinetics of d- and L-carnosine in serum and brain after intravenous (IV) injection in mice. We then investigated the comparative efficacy of d- and l-carnosine in a mouse model of transient focal cerebral ischemia followed by in vitro testing against excitotoxicity and free radical generation using primary neuronal cultures. The pharmacokinetics of d- and l-carnosine were similar in serum and brain after IV injection in mice. Both d- and l-carnosine exhibited similar efficacy against mouse focal cerebral ischemia. In vitro studies in neurons showed protection against excitotoxicity and the accumulation of free radicals. d- and l-carnosine exhibit similar pharmacokinetics and have similar efficacy against experimental stroke in mice. Since humans have far higher levels of carnosinases, d-carnosine may have more favorable pharmacokinetics in future human studies.